Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer

INTRODUCTION: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer (NSCLC) patients. The efficacy of EGFR-TKIs in older patients including poor Eastern Cooperative Oncology Group (ECOG) perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Cheng-Yu, Chen, Chung-Yu, Chang, Shih-Chieh, Lai, Yi-Chun, Wei, Yu-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450762/
https://www.ncbi.nlm.nih.gov/pubmed/34552354
http://dx.doi.org/10.2147/CMAR.S322967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450762/
https://www.ncbi.nlm.nih.gov/pubmed/34552354
http://dx.doi.org/10.2147/CMAR.S322967

Ejemplares similares